Navigation Links
Cardium's Exchange Listing Compliance Plan Accepted by NYSE Amex
Date:1/24/2011

be listed on national exchange, that results observed in one study or using one type of product or procedure will be replicated in subsequent studies or in studies using newly-developed products or procedures, that planned product development efforts and clinical studies can be performed in an efficient and effective manner, that regulatory approvals can be obtained in a timely manner or at all, that partnering, distribution or other commercialization efforts can be achieved, that product modifications or launches will be successful or that the resulting products will be favorably received in the marketplace, that our products or proposed products will prove to be sufficiently safe and effective, that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive, that results or trends observed in one clinical study will be reproduced in subsequent studies, that third parties on whom we depend will behave as anticipated, or that necessary regulatory approvals will be obtained.  Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development, testing and marketing of therapeutic hypothermia devices and the conduct of human clinical trials, including the timing, costs and outcomes of such trials, whether our efforts to launch new devices and systems and expand our markets will be successful or completed within the time frames contemplated, our dependence upon proprietary technology, our ability to obtain necessary funding, regulatory approvals and qualifications, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other
'/>"/>
SOURCE Cardium Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. China Cord Blood Corporation Announces Completion of Warrant Exchange
2. PDL BioPharma Completes Exchange to Retire $92.0 Million of 2.00% Convertible Notes Due August 2012
3. Listing on Frankfurt Stock Exchange for CTI (http://ctinanotech.com)
4. PDL BioPharma Announces Exchange to Retire 2.00% Convertible Senior Notes Due February 15, 2012
5. Inaugural Pharma Exchange Conference Produced by Informex to Draw Together Milwaukee, Wisconsin Chemical Industry
6. China Cord Blood Corporation to Launch Warrant Exchange Offer
7. Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange
8. Advanced Life Sciences CEO Acquires $2 Million of Common Stock Through Debt for Equity Exchange
9. BioMed Realty Trust Announces Planned Filing of Resale Registration Statement in Connection With 3.75% Exchangeable Senior Notes Due 2030
10. HCL Infosystems Joins Hands With Wellogic to Roll Out Nationwide Health Information Exchange Environment Across India
11. NeoStem to Ring Opening Bell at New York Stock Exchange on May 27, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... 16, 2015 Regis Technologies looks forward ... for Cancer Research (AACR) annual meeting. Regis will exhibit ... starting Saturday, April 18, in Philadelphia and running through ... title of the oldest and largest organization focused on ... grants, and partners with survivors to promote awareness and ...
(Date:4/16/2015)... April 16, 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage" ... Exchange: PBT.U), is pleased to announce that the Company ... April 25, 2015 to be held in ... Bailey and Mr. James Mellon , a ... update on the key programs at its subsidiaries, Portage ...
(Date:4/16/2015)... , April 16, 2015  AnaptysBio, Inc., ... of therapeutic antibodies, today announced the advancement ... program into IND-enabling studies. The Company,s anti-IL-36R ... treatment for generalized pustular psoriasis (GPP), an ... medical need. ANB019 is wholly owned within AnaptysBio,s ...
(Date:4/16/2015)... MENLO PARK, Calif. , April 16, 2015 ... and the Company), a biopharmaceutical company focused on developing ... indications, today announced that the Mayo Clinic Cancer ... site for the ongoing, multicenter Phase I/II study of ... most common and deadly form of human brain cancer. ...
Breaking Biology Technology:Regis Technologies Joins American Association for Cancer Research Annual Meeting 2Portage to Present at Master Investor 2015 in London, UK 2Portage to Present at Master Investor 2015 in London, UK 3Portage to Present at Master Investor 2015 in London, UK 4AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5
... Office for Eastern District of Pennsylvania and U.S. Department ... Settles State Cases with Connecticut and Massachusetts, ... today it has finalized a previously announced agreement in,principle ... of,Pennsylvania, the U.S. Department of Justice and various other ...
... exceptional individuals of all ages who,have reached beyond ... ATLANTA, Sept. 29 UCB today announced ... program, which this year awarded a,total of $300,000 ... The scholarship program was established to recognize individuals,of ...
... Bioscience GmbH,announces that it entered into a ... Icon Genetics group. It provides Nomad access ... expression,technology magnICON(R), for manufacturing biomaterials and selected,biosimilar ... provides,Nomad with a strategically needed freedom to ...
Cached Biology Technology:Cephalon Concludes All Outstanding Federal and State Government Investigations into the Company's Sales and Promotional Practices 2Cephalon Concludes All Outstanding Federal and State Government Investigations into the Company's Sales and Promotional Practices 3Cephalon Concludes All Outstanding Federal and State Government Investigations into the Company's Sales and Promotional Practices 4UCB Scholarship Program Awards $300,000 to Students Living with Crohn's Disease 2UCB Scholarship Program Awards $300,000 to Students Living with Crohn's Disease 3UCB Scholarship Program Awards $300,000 to Students Living with Crohn's Disease 4UCB Scholarship Program Awards $300,000 to Students Living with Crohn's Disease 5
(Date:4/2/2015)... 2015 At its 2015 ACMG Annual Clinical ... , the American College of Medical Genetics and Genomics ... its Board.  Members of the ACMG Board of Directors ... and advancing its policies and programs. ACMG is the ... "It,s an eventful time in medical genetics and genomics.  ...
(Date:4/1/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces the second shipment ... underway to early access pre-order customers. ... retail outlets including Walmart, Target, AT&T, Dunkin, Donuts, Stop ... accepted at all outlets and very easy to use. ...
(Date:3/31/2015)... March 31, 2015   Guidepoint , a leading ... the Post-Surgical Pain Management TRACKER, part of the ... trends in the medical device and therapeutics markets. The ... including treatment volumes, market share, and adoption rates across ... with joint surgery. The Post-Surgical Pain Management ...
Breaking Biology News(10 mins):American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... were associated with higher levels of high sensitivity C-Reactive protein ... for heart failure patients, in research presented at the American ... high vitamin C intake from food, heart failure patients in ... times more likely to have higher levels of hsCRP, a ...
... kinase, which has been reported in other cancers such ... driver of the rapid metastasis that patients with inflammatory ... of anaplastic lymphoma kinase (ALK) inhibitors may be a ... of breast cancer. These data were presented at ...
... national panel led by Iowa State University engineers ... technologies that capture, use and sequester carbon while ... security. The 33-member National Panel for a ... time in Chicago. Participants represented universities, companies, federal ...
Cached Biology News:Low vitamin C levels may raise heart failure patients' risk 2Signaling pathway linked to inflammatory breast cancer may drive disease metastasis 2Iowa State engineers establish national panel to advance a carbon negative economy 2Iowa State engineers establish national panel to advance a carbon negative economy 3
Immunogen: Recombinant rabbit tryptophan hydroxylase, isolated as inclusion bodies from E. coli and purified by preparative SDS-PAGE. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Inquire...
... ISOQUANT(R) Isoaspartate Detection Kit is intended for ... proteins and peptides, which can result from ... rearrangement of aspartic acid residues during storage ... depend on the monitoring of charge differences ...
...
Biology Products: